Association of Candidate Diabetic Kidney Disease Loci with T2D-ESKD.

1<p>hg18;</p>2<p>Eff, effective number of SNPs per locus;</p>3<p>RA, reference allele;</p>4<p>OR, odds ratio;</p>5<p>95% CI, 95% confidence interval;</p>6<p>P_Add, additive p-value;</p>7<p>P_emp, empiric p-value;</p>*<p>imputed SNPs.</p

Clinical Characteristics of Study Participants.

*<p>compared to control subjects.</p

Association of Candidate Diabetic Kidney Disease Loci with T2D-ESKD after Adjustment for <i>APOL1</i> G1/G2.

1<p>hg18;</p>2<p>Eff, effective number of SNPs per locus;</p>3<p>RA, reference allele;</p>4<p>OR, odds ratio;</p>5<p>95% CI, 95% confidence interval;</p>6<p>P_Add, additive p-value;</p>7<p>P_emp, empiric p-value;</p>*<p>imputed SNP.</p

Demographic data for liver transplant recipients, based on <i>APOL1</i> genotype of African American deceased donors.

<p>Demographic data for liver transplant recipients, based on <i>APOL1</i> genotype of African American deceased donors.</p

Allograft function outcomes for liver transplant recipients, based on <i>APOL1</i> genotype of African American deceased donors.

<p>Allograft function outcomes for liver transplant recipients, based on <i>APOL1</i> genotype of African American deceased donors.</p

Allograft Survival Time with 0, 1, or 2 <i>APOL1</i> Renal Risk Variants in Donor Liver.

<p>The number of censored events is the difference between the number of transplantations that started the year and the number of events observed during the year. These numbers are shown in parentheses at the bottom of the plot; each color corresponds to a specific <i>APOL1</i> risk group. With a P-value of 0.6491 there is little correlation between liver allograft survival and the <i>APOL1</i> renal risk variants. P-value is from the fully adjusted Cox proportional model.</p

GWAS + Replication, Validation and Overall <i>P</i>-values for susceptibility loci identified from the Overall meta-analysis (P<2.5×10⁻⁵).

<p>SNPs are ordered by chromosome and position (NCBI Build 36.1, hg18) with the major/minor alleles (positive strand) and corresponding gene (underlined) or nearest annotated genes (+/−500 kb). For each phase of the study, GWAS + Replication, Validation and Overall (GWAS+Replication+T2DM+IRAS+IRASFS) analyses, the minor allele frequency (MAF) in controls, additive <i>P</i>-value and odds ratio (OR) with associated 95% confidence interval (CI) with respect to the minor allele is listed.</p

Clinical Characteristics of Study Samples.

<p>Values are presented as trait mean and standard deviation.</p

Study Design.

<p>Study Design.</p

Genome-Wide Association Study Results.

<p>Results are adjusted for admixture using PC1 as a covariate in the analysis. <i>P</i>-values are shown under the additive model. The blue line at -log₁₀(<i>P</i>-value) = 3 represents an additive <i>P</i>-value = 0.001 and the red line at -log₁₀(<i>P</i>-value) = 5 represents a <i>P</i>-value = 1.0×10⁻⁵.</p